Iovance Stock Has Been Hammered. Is This the Buying Opportunity Aggressive Investors Have Been Waiting For?
Source: Motley Fool
2026-06-02 00:35:00 ET
Iovance Biotherapeutics (NASDAQ: IOVA) is not for the faint of heart. While shares in this biotech company are up 50% year to date and over 125% over the past 12 months, the stock has experienced high volatility in the past.
In fact, Iovance is down nearly 80% over the past five years. Results and updates may be better than feared now, but disappointment could still arise. While risk is high, certain factors at play may make Iovance one of the biotech stocks worth a closer look.
Image source: Getty Images.
Iovance Biotherapeutics Inc.
NASDAQ: IOVA
IOVA Trading
-4.78% G/L:
$4.28 Last:
10,141,648 Volume:
$4.50 Open:
IOVA Latest News
June 03, 2026 04:05:00 pm
Iovance's Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
June 02, 2026 12:35:00 am
Iovance Stock Has Been Hammered. Is This the Buying Opportunity Aggressive Investors Have Been Waiting For?
IOVA Stock Data
$1,034,101,562
356,080,269
0.23%
94
N/A
Biotechnology & Life Sciences
Healthcare
US
San Carlos
